Adrenal Cancer Diagnostics Market Report 2026

The adrenal cancer diagnostics market size has grown strongly in recent years. It will grow from $148.54 billion in 2025 to $157.36 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to limited availability of high-resolution imaging modalities, growing prevalence of adrenal tumors, rising awareness about adrenal cancer, reliance on conventional biopsy techniques, increasing hospital infrastructure.

The adrenal cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $206.14 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to advancement in contrast-enhanced imaging technologies, growth in targeted adrenal cancer therapies, rising adoption of pet-ct combination scans, expansion of specialized cancer centers, increasing government funding for cancer diagnostics. Major trends in the forecast period include rising adoption of advanced imaging techniques for adrenal cancer, increasing use of minimally invasive biopsy procedures, growth in targeted cancer therapy applications, expansion of multidisciplinary cancer diagnostic centers, enhanced focus on early detection and personalized treatment.

The increasing prevalence of cigarette smoking is expected to drive the growth of the adrenal cancer diagnostics market going forward. Cigarette smoking involves inhaling and exhaling the smoke from burning tobacco, which contains nicotine, an addictive alkaloid with both stimulating and calming psychoactive effects. Cigarette smoking has been linked to a higher risk of adrenal cancers, including adrenal adenomas and adrenocortical carcinomas. Carcinogenic compounds present in tobacco smoke can damage the DNA of adrenal cells, leading to genetic mutations that may result in cancer. For instance, in August 2024, according to Statistics Canada, a Canada-based government agency, Canadian manufacturers produced 1.2 billion cigarettes in July 2024, representing a 4.3% increase from June 2024 and a 2.3% rise compared with July 2023. Therefore, the rising rate of cigarette smoking is fueling the growth of the adrenal cancer diagnostics market.

Major companies operating in the adrenal cancer diagnostics market are launching innovative initiatives through advanced collaboration models, such as the CancerX Startup Accelerator, to accelerate digital innovation in cancer care. The accelerator is designed to support high-potential startups by offering mentorship, training, and direct access to major healthcare stakeholders, including providers and pharmaceutical companies. For instance, in November 2023, CanceRx, LLC, a US-based public-private partnership focused on advancing cancer innovation, announced the launch of this initiative at the Future of Cancer Care Summit held in Tampa, Florida. The program plans to select its inaugural cohort of approximately 15 to 20 companies beginning in March 2024, concentrating on key areas such as clinical research, screening, diagnosis, and treatment. The initiative is expected to meaningfully support the objectives of the Cancer Moonshot by addressing gaps in cancer care and encouraging the development of impactful digital oncology solutions.

In June 2023, Quest Diagnostics, a US-based medical laboratory services company, acquired Haystack Oncology, Inc. for an undisclosed amount. Through this acquisition, Quest Diagnostics will integrate Haystack Oncology’s minimal residual disease (MRD) testing technology, which is based on circulating tumor DNA (ctDNA), into its diagnostic offerings. Haystack Oncology, Inc. is a US-based biotechnology company.

Major companies operating in the adrenal cancer diagnostics market are Johnson And Johnson Pvt Ltd., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Abbott Laboratories, Siemens Healthcare GmbH, Becton Dickinson and Company, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Agilent Technologies, Hologic Inc., PerkinElmer Inc., Illumina Inc., Roche Diagnostics, BioMerieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., Bruker Corporation, Exact Sciences Corp., Natera Inc., Invitae Corporation, Qiagen NV, Guardant Health Inc., Foundation Medicine Inc., NanoString Technologies Inc.

North America was the largest region in the adrenal cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adrenal cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adrenal cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the adrenal cancer diagnostics market by increasing costs for imported imaging equipment, contrast agents, and biopsy instruments. Segments such as MRI, CT scans, and PET-CT scans are most affected, particularly in north america, europe, and asia-pacific regions. This has resulted in higher procedure costs and extended procurement timelines. On the positive side, tariffs are encouraging domestic manufacturing, local sourcing of diagnostic tools, and investment in regional healthcare infrastructure.

The adrenal cancer diagnostics market research report is one of a series of new reports that provides adrenal cancer diagnostics market statistics, including adrenal cancer diagnostics industry global market size, regional shares, competitors with a adrenal cancer diagnostics market share, detailed adrenal cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the adrenal cancer diagnostics industry. This adrenal cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Adrenal cancer diagnostics refers to the process of detecting and diagnosing cancer that originates in the adrenal glands, which are located above the kidneys. This process includes a range of medical evaluations, tests, and procedures used to determine the presence of adrenal cancer and is critical for effective treatment planning and disease management.

The main tests used in adrenal cancer diagnostics include magnetic resonance imaging (MRI), computed tomography (CT) scans, X-rays, positron emission tomography (PET) scans, and biopsy. Magnetic resonance imaging (MRI) is a medical imaging method that uses strong magnetic fields and radio waves to generate detailed, high-resolution images of internal body structures. Treatment options include surgery, chemotherapy, radiotherapy, targeted cancer therapies, and others for conditions such as pheochromocytoma, adrenocortical carcinoma, and other tumor types. These procedures are performed by end users including hospitals, ambulatory surgical centers, cancer centers, and others.

The adrenal cancer diagnostics market consists of revenues earned by entities by providing genetic testing, histopathology, blood tests, and dexamethasone suppression tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The adrenal cancer diagnostics market also includes sales of ultrasound machines, reagents and test kits, microscopes, histology kits, and microtomes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.